Beta-zeacarotene

Other Names

7',8'-Dihydro-beta,psi-carotene7',8'-dihydro-β,ψ-carotenebeta,psi-carotenezeacaroteneβ,ψ-caroteneβ-Zeacarotene

Synopsis

Beta-Zeacarotene: An Encyclopedic Reference

1. Identity, Chemistry, and Nomenclature

Chemical Names and Identifiers

Beta-zeacarotene (also written as β-zeacarotene) is a naturally occurring carotenoid hydrocarbon. β-Zeacarotene is a carotenoid. Its systematic IUPAC name is 7′,8′-dihydro-β,ψ-carotene, reflecting the fact that it is a partially saturated, monocyclic analogue of beta-carotene in which one of the two terminal rings has been replaced by an acyclic (ψ, or psi) end group. The β-carotene hydroxylase product converts the monocyclic β-zeacarotene (7′,8′-dihydro-β,ψ-carotene) to hydroxy-β-zeacarotene (7′,8′-dihydro-β,ψ-carotene-3-ol). The compound is registered in PubChem under CID 5280790, with the molecular formula C₄₀H₅₈. Its chemical formula is C₄₀H₅₈ (PubChem CID 5280790), and its InChIKey is MICBIPJWKDDGNL-FILYMEKXSA-N. It also carries ChEBI ID 27533 and a Reaxys registry number of 2571810.

Beta-zeacarotene differs from its close relative beta-carotene (C₄₀H₅₆) by possessing two additional hydrogen atoms: a partial double-bond reduction at the 7′,8′ position means one terminal ring (the β-ionone ring) is present while the other end remains as an open-chain psi (ψ) group. This makes beta-zeacarotene a monocyclic carotene, whereas beta-carotene is bicyclic (bearing a β-ionone ring at both ends). The molecule belongs to the broader class of carotenes — carotenoids constructed only of carbon and hydrogen are classified as carotenes, while carotenoids containing an oxygen element in addition to carbon and hydrogen are classified as xanthophylls.

Position in the Carotenoid Family

From a chemical standpoint, beta-zeacarotene is classified as a tetraterpene, containing 40 carbon atoms. It features a conjugated double-bond system that gives it its characteristic color and biological activity. Structurally, beta-zeacarotene is closely related to other carotenoids like beta-carotene and lycopene, but it occupies a unique place as an intermediate in the biosynthesis of beta-carotene.

Because it lacks one of the two β-ionone rings found in beta-carotene, beta-zeacarotene has a shorter effective conjugated chromophore than beta-carotene, and its optical absorption spectrum is correspondingly blue-shifted relative to fully cyclized bicyclic carotenoids. The compound exists primarily in the all-trans (all-E) configuration.

Common Forms and Preparations

Beta-zeacarotene is used as a coloring agent in the food and pharmaceutical industries. In research and industrial contexts it is detected and quantified from biological extracts (fungi, algae, plant tissue) predominantly by reverse-phase HPLC with diode-array detection (RP-HPLC-DAD). Peak identification is achieved by comparing retention time with authentic standards and confirmed by spiking and comparison of spectral data; for neurosporene, γ-carotene, ζ-carotene, β-zeacarotene and 7,8-dihydro-β-carotene, their identification is based on elution order and spectral data in the visible region with regard to published information. It is not currently available as a standalone dietary supplement dosage form and is not recognized under a discrete food-additive number (E number) in the way that beta-carotene is, but it is detected as a minor constituent in carotenoid-rich extracts derived from fungal fermentation (such as those from Blakeslea trispora), algae, and plant sources.

2. Discovery and Historical Background

First Identification (1953)

β-Zeacarotene is a carotenoid used as a coloring agent in the food and pharmaceutical industries. First reported in 1953, it was discovered to occur in small quantities when the fungus Phycomyces blakesleeanus was grown with diphenylamine, a compound that inhibits the synthesis of beta-carotene. The compound initially appeared in the scientific literature under the provisional designation "Pigment X." Pigment "X" reported in diphenylamine-inhibited cultures of Phycomyces blakesleeanus in 1953 by Goodwin and Osman has been identified as β-zeacarotene. The original material also contained traces of ζ-carotene. The original report (Goodwin, Jamikorn, and Willmer) appeared in the Biochemical Journal: Goodwin T.W., Jamikorn M., Willmer J.S., "Studies in carotenogenesis. 7. Further observations concerning the action of diphenylamine in inhibiting the synthesis of beta-carotene in Phycomyces blakesleeanus," Biochem J. 1953 Mar; 53(4): 531–538.

Subsequent Identification in Other Organisms

Following its identification in Phycomyces blakesleeanus, beta-zeacarotene was subsequently characterized in other organisms. An examination of the carotene fractions extracted from Euglena gracilis Z and pressure-bleached Euglena mutants PR-1, PR-2, PR-3, and PR-4 revealed phytoene in several mutants. With the exception of PR-4, in which no C40 carotenoids were detected, the following carotenes were identified in all from their mass spectra: phytoene, phytofluene, ζ-carotene, β-zeacarotene, and β-carotene. Of these, phytoene and β-zeacarotene had not previously been unequivocally identified in Euglena. This work, published in Plant Physiology in 1975, confirmed that beta-zeacarotene is a genuine biosynthetic intermediate rather than an artifact of chemical inhibition.

Beta-zeacarotene does not have a documented history of intentional traditional or ethnobotanical use by any human culture, because it was entirely unknown until the mid-twentieth century and occurs only in trace or minor amounts as a metabolic intermediate or by-product in organisms rather than as a primary accumulated pigment in edible food plants. No traditional-use history can be verified for beta-zeacarotene in any pharmacopeial, ethnobotanical, or historical source. The broader class of carotenoids has millennia of dietary exposure via pigmented fruits and vegetables, but beta-zeacarotene specifically was identified through laboratory biochemistry, not through traditional medicine.

3. Natural Sources and Occurrence

Fungi

Beta-zeacarotene is found in carotenoid-producing fungi, particularly those of the order Mucorales. Several fungi of the order Mucorales synthesize β-carotene; they include Phycomyces blakesleeanus, Choaneophora cucurbitarum, and Blakeslea trispora. In these organisms, beta-zeacarotene accumulates as an intermediate when the normal carotenoid biosynthesis pathway is perturbed — either by the action of specific inhibitors such as diphenylamine or through mutations in the phytoene desaturase gene. Compounds which cause an accumulation of lycopene and γ-carotene usually cause an increase in phytoene synthesis and the disappearance of β-zeacarotene. When β-picoline and 2-methylimidazole treated C115 mycelia were washed and resuspended in phosphate buffer at pH 5.6, β-zeacarotene reappeared and β-carotene increased with the simultaneous decrease in lycopene and γ-carotene.

Beta-zeacarotene has been detected in cultures of Blakeslea trispora and Fusarium fujikuroi (Gibberella fujikuroi). Phytoene, phytofluene, ζ-carotene, β-zeacarotene, γ-carotene, β-carotene, torulene, and neurosporaxanthin are among the carotenoids found in Fusarium fujikuroi. In the case of F. fujikuroi CarB, the identification of β-zeacarotene implies the release of neurosporene by an eventual CarB complex and the latter incorporation of the cyclized substrate.

Algae and Photosynthetic Microorganisms

Euglena gracilis is a freshwater species of euglenid, a microscopic type of algae, in the genus Euglena. This organism is a confirmed natural source: Wikidata records, cross-referencing PubChem CID 5280790, that beta-zeacarotene is found in the taxon Euglena gracilis. Beta-zeacarotene has also been detected in photosynthetic bacteria, where the enzyme neurosporene cyclase (lycopene cyclase acting on neurosporene as a substrate) generates it as a monocyclic product.

Higher Plants and Other Organisms

In higher plants, beta-zeacarotene functions strictly as a transient metabolic intermediate in the carotenoid biosynthesis pathway and does not typically accumulate in plant tissues under normal physiological conditions. It is not a common constituent of edible plant foods and has no recognized dietary significance at normal exposure levels. Its detection in dinoflagellates has also been documented: its identity was confirmed in studies of mutants of the dinoflagellate Crypthecodinium cohnii.

4. Biosynthesis: Position in the Carotenoid Pathway

Overview of the Carotenoid Pathway

Carotenoids are 40-carbon terpenoids having eight connected isoprene units. Carotenoids include phytoene, zeta-carotene, lycopene, beta-carotene, zeaxanthin, and zeaxanthin diglucoside. The pathway leading from the first committed C40 precursor, phytoene, to the major cyclic carotenoids involves sequential desaturation and then cyclization steps:

In a pathway for synthesizing a carotenoid having 40 carbon atoms, phytoene is synthesized by condensation of two molecules of C20PP with a phytoene synthase (CrtB), and serves as a precursor for a carotenoid backbone compound. Phytofluene, ζ-carotene, neurosporene, lycopene, tetradehydrolycopene, and the like are synthesized by sequential desaturation of phytoene. Various carotenoids such as α-carotene, β-carotene, γ-carotene, δ-carotene, ε-carotene, lutein, zeaxanthin, canthaxanthin, fucoxanthin, astaxanthin, antheraxanthin, and violaxanthin are synthesized by modification of the ends of lycopene through cyclization or oxidation.

Beta-Zeacarotene as a Monocyclic Intermediate

Beta-zeacarotene arises specifically from the lycopene cyclase (lycopene β-cyclase; EC 5.5.1.19) acting on neurosporene (7,8-dihydro-ψ,ψ-carotene) rather than on lycopene itself. Lycopene β-cyclase also acts on neurosporene to give β-zeacarotene. The reaction involves introduction of a single β-ionone ring at the more-unsaturated terminus of the neurosporene molecule, yielding the monocyclic product.

This relationship was definitively characterized in a landmark study of lycopene cyclase from the cyanobacterium Synechococcus sp. strain PCC7942: the crtL gene product converts the acyclic hydrocarbon lycopene into the bicyclic beta-carotene, an essential component of the photosynthetic apparatus in oxygen-evolving organisms and a source of vitamin A in human and animal nutrition. The enzyme also converts neurosporene to the monocyclic beta-zeacarotene but does not cyclize zeta-carotene, indicating that desaturation of the 7-8 or 7′-8′ carbon-carbon bond is required for cyclization. The bleaching herbicide MPTA effectively inhibits both cyclization reactions.

The same catalytic versatility was demonstrated with purified lycopene cyclase from Erwinia uredovora: lycopene cyclase, an enzyme responsible for the formation of cyclic carotenoids from acyclic precursors, was characterized as catalyzing a two-step reaction in which both sides of the lycopene molecule are cyclized to beta-ionone rings with the monocyclic gamma-carotene as an intermediate. Furthermore, neurosporene as well as 1-hydroxylycopene were cyclized to beta-zeacarotene and hydroxy-γ-carotene respectively.

Multiple lycopene cyclase enzymes from diverse taxonomic groups — including bacteria, higher plants, and cyanobacteria — have been shown to catalyze this reaction: both CrtY and CrtL enzymes are capable of performing two successive β-cyclization reactions to convert acyclic lycopene to bicyclic β-carotene via monocyclic γ-carotene, and to convert acyclic neurosporene to bicyclic dihydro-β-carotene (7,8-dihydro-β,ψ-carotene) via monocyclic β-zeacarotene.

Work with Arabidopsis thaliana cyclases confirmed that the beta-cyclase, but not the epsilon-cyclase, gives beta-zeacarotene from neurosporene: the products formed from neurosporene via the action of the Arabidopsis lycopene cyclase cDNA products are the monocyclic compounds α-zeacarotene (7′,8′-dihydro-ε,ψ-carotene) and β-zeacarotene (7′,8′-dihydro-β,ψ-carotene) respectively.

Similarly, lycopene cyclases from the higher plant Capsicum annuum also produce beta-zeacarotene from neurosporene as an obligate monocyclic intermediate en route to 7,8-dihydro-β-carotene: introduction of the lycopene cyclase gene from E. uredovora (crtY) or the higher plant Capsicum annuum (Icy) resulted in the production of a bicyclic carotenoid, 7,8-dihydro-beta-carotene, via monocyclic beta-zeacarotene.

Further Metabolism of Beta-Zeacarotene

Once formed, beta-zeacarotene can serve as a substrate for downstream enzymes. The product of the A. thaliana β-carotene hydroxylase cDNA converts the monocyclic β-zeacarotene (7′,8′-dihydro-β,ψ-carotene) to hydroxy-β-zeacarotene (7′,8′-dihydro-β,ψ-carotene-3-ol). The monocyclic β-zeacarotene was efficiently converted to hydroxy-β-zeacarotene.

In the plant carotenoid pathway, neurosporene itself is produced from zeta-carotene by zeta-carotene desaturase (ZDS): ζ-Carotene desaturase (ZDS) then dehydrogenates 9,9′-di-cis-ζ-carotene to 7,9,9′-tri-cis-neurosporene and 7,7′,9,9′-tetra-cis-lycopene successively. Beta-zeacarotene therefore sits at the junction of the desaturation and cyclization branches, being formed when lycopene cyclase intercepts the partially desaturated intermediate neurosporene before it has been fully converted to lycopene.

5. Key Constituents and Structural-Activity Relationships

Conjugated Chromophore

Carotenoids are widespread terpenoid pigments with applications in the food and feed industries. The biological activities of carotenoids, including potential antioxidant properties, arise from their extended system of conjugated carbon-carbon double bonds. Beta-zeacarotene features a conjugated double-bond system that gives it its characteristic color and biological activity. Because beta-zeacarotene has one fewer ring and a partially reduced end group relative to beta-carotene, it has a shorter effective conjugation length and therefore absorbs at shorter wavelengths, imparting a yellow hue rather than the deep orange of beta-carotene.

Relationship to Provitamin A Activity

Beta-carotene's provitamin A activity depends on the presence of a beta-ionone ring: the enzyme beta-carotene 15,15′-monooxygenase cleaves the central carbon-carbon double bond of beta-carotene to yield two molecules of retinal. The one clear function of certain carotenoids that is firmly linked to a health outcome is the provitamin A activity of some dietary carotenoids (α-carotene, β-carotene, and β-cryptoxanthin) and their role in the prevention of vitamin A deficiency. Beta-zeacarotene possesses only one beta-ionone ring; accordingly, its theoretical maximum provitamin A potential — if any — would be substantially lower than that of beta-carotene (which has two beta-ionone rings). No peer-reviewed human or animal study specifically quantifying the provitamin A conversion efficiency of beta-zeacarotene has been identified in the literature. It should not be assumed to have the same provitamin A potency as beta-carotene.

Antioxidant Potential

Carotenoids with conjugated double-bond systems are capable of quenching singlet oxygen and scavenging peroxyl radicals. As an antioxidant, beta-carotene quenches singlet molecular oxygen and scavenges reactive oxygen species, especially peroxyl radicals. Singlet oxygen quenching is likely to be restricted to the skin as the only light-exposed tissue that contains higher levels of β-carotene; other carotenoids demonstrate similar activity. Upon radical scavenging, β-carotene decomposes and cannot be regenerated. Beta-zeacarotene, sharing structural features with beta-carotene, would be expected on theoretical grounds to possess qualitatively similar antioxidant properties, but no human clinical study or validated in-vivo antioxidant study specifically for beta-zeacarotene has been identified. In-vitro studies on beta-zeacarotene in isolation are not well-documented in the peer-reviewed literature accessible through major databases.

6. Scientific Evidence by Area of Use

The following section surveys what the peer-reviewed literature supports. It is essential to state clearly at the outset: beta-zeacarotene has not been the subject of dedicated human clinical trials, randomized controlled trials, systematic reviews, or meta-analyses. The compound is primarily described in the biochemical and molecular biology literature as a biosynthetic intermediate and a minor pigment constituent. Where health-related claims have been associated with it, these relate to the broader carotenoid class or to the closely related compound beta-carotene; such evidence is not directly transferable to beta-zeacarotene without specific studies. The following characterizes what is and is not known.

6.1 Colorant / Pigment Application

Evidence level: Established (industrial/regulatory context). Beta-zeacarotene is used as a coloring agent in the food and pharmaceutical industries. This use reflects the compound's chromophoric properties arising from its conjugated system. Beta-carotene, the closely related bicyclic congener, has extensive regulatory status as a food color; beta-zeacarotene, however, does not have its own independent regulatory approval as a food color additive in the way beta-carotene does under, for example, 21 CFR §73.95 (which pertains specifically to beta-carotene, C₄₀H₅₆). No specific regulatory approval document for beta-zeacarotene as an isolated color additive was identified in authoritative regulatory databases (FDA, EFSA, or WHO); its coloring use appears to be incidental when it co-occurs in carotenoid-rich extracts.

6.2 Carotenoid Biosynthesis Research Tool

Evidence level: Established (biochemical research). Beta-zeacarotene's most scientifically documented role is as a diagnostic intermediate in carotenoid pathway research. It is used as a biomarker to identify the extent of cyclase activity in organisms accumulating neurosporene. Compounds which cause an accumulation of lycopene and γ-carotene usually cause an increase in phytoene synthesis and the disappearance of β-zeacarotene. Its accumulation or disappearance in microbial or plant extracts analyzed by HPLC informs researchers about the activity of lycopene cyclase genes and the flux through the carotenoid pathway.

6.3 Potential Antioxidant / Health-Promoting Properties

Evidence level: Speculative; no human data for beta-zeacarotene specifically. The biological and health-related rationale for beta-zeacarotene is extrapolated from the extensive literature on beta-carotene and other carotenoids. Research studies and epidemiological data have shown that antioxidants such as vitamin E and carotenoids such as β-carotene, lycopene, lutein, and zeaxanthin contribute to preventing degenerative diseases, such as cardiovascular diseases, diabetes, and several types of cancers. However, these findings apply to carotenoids that are significant dietary constituents consumed in gram-level quantities over a lifetime; beta-zeacarotene is not established as a dietary constituent of similar significance. This class of phytoconstituents has witnessed a broad research gap due to several twin conclusions that have been reported. No randomized trial, observational epidemiological study, or validated clinical pharmacokinetic study specifically investigating beta-zeacarotene in humans exists in the literature consulted.

6.4 Provitamin A / Vitamin A Deficiency

Evidence level: Theoretical; no human data for beta-zeacarotene specifically. Beta-zeacarotene's monocyclic structure means it retains one beta-ionone ring, which is the structural requirement for provitamin A activity. However, the established provitamin A carotenoids in human nutrition are alpha-carotene, beta-carotene, and beta-cryptoxanthin: the one clear function of certain carotenoids that is firmly linked to a health outcome is the provitamin A activity of some dietary carotenoids (α-carotene, β-carotene, and β-cryptoxanthin) and their role in the prevention of vitamin A deficiency. Beta-zeacarotene is not listed among these, nor does any National Institutes of Health or EFSA opinion assign it a retinol equivalency factor. Claims regarding its provitamin A activity cannot be substantiated with current clinical evidence.

6.5 Photoprotection

Evidence level: No direct evidence for beta-zeacarotene; indirect basis from beta-carotene literature. Studies demonstrated the photoprotective effects of β-carotene on photooxidative damage and sunburn in humans. A significant reduction in erythema formation was noticed when β-carotene was applied on human skin or with a dietary intervention alone or in combination with α-tocopherol for 12 weeks. No parallel studies for beta-zeacarotene exist.

7. Body Systems and Health Areas of Association

On the basis of its structural similarity to beta-carotene and its membership in the carotenoid family, beta-zeacarotene has been discussed in the context of the following body systems, though it is critical to note that the evidence for beta-zeacarotene specifically in any of these areas is absent or only indirectly inferred from other carotenoids:

Visual system / eye health: Carotenoids in the retinal pigment are primarily lutein and zeaxanthin, not beta-zeacarotene. The relevance of beta-zeacarotene to eye health is unestablished.
Immune modulation: Reactive oxygen species are formed extensively during inflammatory processes intended to render germs harmless. Beta-carotene, working together with other antioxidants, ensures balanced regulation of oxidative processes occurring during elimination of harmful microorganisms without allowing excess free radicals to damage immune cells. Whether beta-zeacarotene shares this role is unknown.
Cardiovascular system: Low concentrations of serum β-carotene have been associated with an increased risk of congestive heart failure and cardiac death in men. No equivalent association has been demonstrated for beta-zeacarotene.
Skin: Carotenoids accumulate in skin tissue and may provide photoprotection. Beta-zeacarotene's coloring and antioxidant chromophore properties have been noted in industrial pigmentation use.
Food coloring / pharmaceutical coloring: This is the most directly documented application. Beta-zeacarotene is used as a coloring agent in the food and pharmaceutical industries.

8. Dosage Forms and Reported Dosages

Beta-zeacarotene is not available as a standalone dietary supplement product in any formulation that has been the subject of clinical trial dosing. It is not assigned a recommended dietary allowance (RDA), adequate intake (AI), tolerable upper intake level (UL), or any other dietary reference value by any national or international health authority. No human clinical pharmacokinetic study reporting oral doses, blood level measurements, or dose-response data for isolated beta-zeacarotene has been identified in peer-reviewed literature or in government health agency databases (NIH ODS, EFSA, WHO).

In the context of industrial fermentation studies examining carotenoid profiles, beta-zeacarotene has been detected by RP-HPLC-DAD as a quantitatively minor component of total carotenoid extracts, and its relative quantity in grams per gram dry mass or in µg/g has been reported only in comparison with major carotenoids (such as beta-carotene). For example, in studies of Fusarium fujikuroi, intermediate quantities are indicated in µg per gram dry mass. These are production/analytical measurements in microbial cultures, not human dosing data.

For comparison, clinical dosage data for the structurally related compound beta-carotene (for which there are clinical trial data) include: beta-carotene is used for the prevention of sunburns and photodamage, erythropoietic protoporphyria, psoriasis, vitiligo, and hairy leukoplakia in doses of 6–15 mg per day in adults. Separate dosages are used in erythropoietic protoporphyria — 150–180 mg per day — and prevention of sunburns: 25 mg per day. These beta-carotene doses cannot be extrapolated to beta-zeacarotene without dedicated pharmacological investigation.

9. Safety Considerations and Interactions

Direct Safety Data for Beta-Zeacarotene

No dedicated human toxicology study, regulatory safety assessment, or adverse-event report for isolated beta-zeacarotene was identified in any authoritative source. It is not listed in the FDA's 21 CFR color additive regulations for foods or drugs as an independently approved substance distinct from beta-carotene. EFSA and the WHO/FAO Joint Expert Committee on Food Additives (JECFA) have not issued an opinion on beta-zeacarotene as a stand-alone substance.

Safety Inferences from the Broader Carotenoid Literature

Given beta-zeacarotene's structural and metabolic relationship to beta-carotene, the following safety data from the beta-carotene literature provide contextual — but not directly applicable — reference points:

Prooxidant risk at high oxygen tension: Some studies do not favor the absolute supplementation of high doses of β-carotene because the initial antioxidant activity of β-carotene is followed by a prooxidant action at high oxygen tension, which may be related to its adverse effects.
Risk in smokers (beta-carotene data only): In those who smoke tobacco, beta-carotene can increase the risk of lung cancer. Whether this risk would apply to beta-zeacarotene is entirely speculative; the mechanism(s) proposed for the beta-carotene-lung-cancer association in smokers (e.g., the ATBC and CARET trials) have not been examined for beta-zeacarotene.
Carotenemia (skin yellowing): High intake of carotenoids generally can result in carotenemia (reversible yellowing of the skin). This has been documented for beta-carotene but not investigated specifically for beta-zeacarotene.
No established upper limit: While there is evidence that β-carotene is an antioxidant in vitro, its importance to health is not known. No tolerable upper limit for beta-zeacarotene has been established by any regulatory authority.
EFSA safety opinion (beta-carotene reference): The EFSA FEEDAP Panel concluded that the use of beta-carotene in animal nutrition under approved conditions remains safe for target species, consumers, and the environment. This opinion pertains to beta-carotene (CAS 7235-40-7), not beta-zeacarotene.

Drug and Nutrient Interactions

No interaction data specific to beta-zeacarotene have been published. The following known interactions of beta-carotene — the structurally most similar compound with a clinical dataset — are noted for contextual awareness only and should not be assumed to apply equally to beta-zeacarotene without evidence:

High-dose beta-carotene supplementation has been associated with reduced absorption of other fat-soluble carotenoids (competitive intestinal absorption).
Certain cholesterol-lowering medications (statins, bile acid sequestrants) have been observed to reduce carotenoid absorption in clinical settings.
Proton-pump inhibitors and drugs reducing gastric acid output may impair carotenoid bioavailability from food sources.

None of the above interactions have been specifically investigated for beta-zeacarotene.

10. Summary of Evidence Characterization

Beta-zeacarotene is a well-characterized biochemical entity whose chemical identity, biosynthetic origin, and occurrence in specific microbial and algal organisms is firmly established in the peer-reviewed literature. Its primary documented role is as a monocyclic carotenoid intermediate in the enzymatic pathway leading from neurosporene to beta-carotene, catalyzed by lycopene beta-cyclase. Its use as a coloring agent in food and pharmaceutical manufacturing is noted but lacks a dedicated regulatory dossier comparable to that of beta-carotene.

As a dietary supplement or health-promoting ingredient, beta-zeacarotene currently lacks any human clinical trial evidence. All health-related properties discussed in the popular supplement literature for beta-zeacarotene are inferred by analogy from beta-carotene or the carotenoid class in general and cannot be attributed to beta-zeacarotene on the basis of current scientific evidence. Researchers and formulators should not treat beta-zeacarotene as biochemically equivalent to beta-carotene for provitamin A activity, antioxidant capacity, or clinical efficacy without specific supporting data.

References

Health Conditions

Health conditions that Beta-zeacarotene may help support.

No conditions available.

Body Systems

Body systems that Beta-zeacarotene may help support.

No body systems available.